Zonisamide has beneficial effects on Parkinson's disease patients

被引:114
作者
Murata, M [1 ]
Horiuchi, E [1 ]
Kanazawa, I [1 ]
机构
[1] Univ Tokyo, Grad Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 1138655, Japan
关键词
zonisamide; Parkinson's disease; levodopa; anticonvulsant;
D O I
10.1016/S0168-0102(01)00298-X
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Zonisamide (ZNS) is a generally well tolerated anticonvulsant that has beneficial effects on Parkinson's disease (PD). ZNS (300 mg/day) given to a patient with PD who incidentally had convulsive attacks, ameliorated the attacks and, surprisingly, his parkinsonian symptoms. We, therefore, carried out an open trial of ZNS on nine patients with PD. Patients were given 50-200 mg/day ZNS in addition to their anti-PD drugs. Seven clearly showed lessening of symptoms, especially wearing-off. We speculate that long lasting activation of dopamine synthesis by ZNS ameliorates parkinsonian symptoms, in particular wearing-off. (C) 2001 Elsevier Science Ireland Ltd and the Japan Neuroscience Society. All rights reserved.
引用
收藏
页码:397 / 399
页数:3
相关论文
共 50 条
  • [11] Zonisamide Ameliorates Microglial Mitochondriopathy in Parkinson's Disease Models
    Tada, Satoshi
    Choudhury, Mohammed E.
    Kubo, Madoka
    Ando, Rina
    Tanaka, Junya
    Nagai, Masahiro
    BRAIN SCIENCES, 2022, 12 (02)
  • [12] The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice
    Sano, Hiromi
    Nambu, Atsushi
    NEUROCHEMISTRY INTERNATIONAL, 2019, 124 : 171 - 180
  • [13] Beneficial Effects of Flavonoids Against Parkinson's Disease
    Jung, Un Ju
    Kim, Sang Ryong
    JOURNAL OF MEDICINAL FOOD, 2018, 21 (05) : 421 - 432
  • [14] The pharmacology for zonisamide to treat Parkinson's disease
    Lu, Chengqi
    Xu, Zeren
    Wang, Pei
    Fan, Jiajia
    Zhou, Xiaowen
    Zhang, Zhengqiong
    Xu, Sichuan
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2021, 128 : 245 - 246
  • [15] Randomized placebo-controlled trial of zonisamide in patients with Parkinson's disease
    Murata, Miho
    Hasegawa, Kazuko
    Kanazawa, Ichiro
    Shirakura, Kenji
    Kochi, Kenji
    Shimazu, Rieko
    NEUROLOGY AND CLINICAL NEUROSCIENCE, 2016, 4 (01): : 10 - 15
  • [16] Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease
    Ueno, Shin-Ichi
    Saiki, Shinji
    Fujimaki, Motoki
    Takeshige-Amano, Haruka
    Hatano, Taku
    Oyama, Genko
    Ishikawa, Kei-Ichi
    Yamaguchi, Akihiro
    Nojiri, Shuko
    Akamatsu, Wado
    Hattori, Nobutaka
    CELLS, 2019, 8 (01)
  • [17] Sexually Dimorphic Effect of Zonisamide on Behavioral Locomotor Activity in a Rat Model of Parkinson's disease
    Moayeri, Ardeshir
    Khalili, Zynab
    Darvishi, Marzieh
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND PHYTOPHARMACOLOGICAL RESEARCH, 2019, 9 (05): : 27 - 36
  • [18] Behavioral effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice
    Sano, Hiromi
    Nambu, Atsushi
    FRONTIERS IN AGING NEUROSCIENCE, 2023, 15
  • [19] Zonisamide in Parkinson’s DiseaseProfile Report
    Lily P. H. Yang
    Caroline M. Perry
    Drugs & Aging, 2010, 27 : 73 - 75
  • [20] Effectiveness of zonisamide in a patient with Parkinson's disease and various levodopa-induced psychotic symptoms
    Yabe, Ichiro
    Ohta, Midori
    Egashira, Toshiaki
    Sato, Kazunori
    Kano, Takahiro
    Hirotani, Makoto
    Kunieda, Yasuyuki
    Sasaki, Hidenao
    NEUROLOGY AND CLINICAL NEUROSCIENCE, 2014, 2 (06): : 201 - 203